Waters aims to redefine lab science with new liquid chromatography solution

Waters Corporation has released the Acquity Premier liquid chromatography solution featuring its MaxPeak High Performance Surface (HPS) technology. The solution leverages HPS to vastly improve analytical data quality and eliminate the need for time-consuming and costly passivation, says Waters.

Acquity Premier is designed to alleviate the problem of analyte/metal surface interactions when analysing organic acids, organophosphates, oligonucleotides, phosphopeptides, acidic glycans and phospholipids by reversed phase and hydrophilic interaction chromatography.

For these analyses, the new system solution cuts the time from sample to results, improves analyte recovery and assay-to-assay reproducibility, to give separation scientists greater assurance in the integrity of their qualitative and quantitative analytical results.

“The Acquity Premier solution represents our biggest innovation in separation science since UPLC,” said Ian King, Senior Vice President, Global Products, Waters Corporation. “Chromatography has an immeasurable impact on the development of novel therapeutics and treatments for innumerable diseases. The result of decades of separations science know-how along with the combined efforts of our materials scientists, chemists and engineers, Acquity Premier addresses a long-standing problem that has held back scientific progress long enough. We firmly believe it will redefine the value that separations science brings to scientific achievement.”

MaxPeak HPS technology is a hybrid organic/inorganic surface technology that forms a barrier between the sample and the metal surfaces of both the system and column. By mitigating, or eliminating altogether, non-specific adsorption, the Acquity Premier Solution offers many benefits, says Waters, which includes: Increased analyte recovery with 10-100X improvement in detection sensitivity for low-level phosphorylated and carboxylated analytes reducing the risk of unseen analytes going undetected; sharper peak shapes and greater peak capacity for more accurate analyte identification and data interpretation, and greater reproducibility for separations prone to adsorptive losses meaning less re-work or troubleshooting, and more confidence in results.

“This approach solves a real problem with the analysis of some particularly troublesome analytes,” said noted expert and consultant Prof. Ian Wilson, Faculty of Medicine, Dept. of Metabolism, Digestion and Reproduction, Imperial College London. “The improvements in peak shape and signal-to-noise ratio at low concentrations of analytes like phosphorylated drugs and lipids are obvious at a glance and very impressive, and it will make the lives of many analysts much easier.”

 

 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free